Abstract: The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1, R2—COO—[—CH(CH3)—COO]n—R1??Formula 1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula 2, R2—COO—[—CH2—COO]n—R1??Formula 2 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a lactate ester of formula 3, HO—CH(CH3)—COO—R22??Formula 3 and/or a glycolic acid ester of formula 4, HO—CH2—COO—R2??Formula 4 wherein R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The compound, which preferably is a lactylate or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, is particularly useful in the treatment or prevention of Clostridia. An animal nutrition composition and a method for preventing or treating infections are also claimed.

Abstract: The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: a) a discontinuous oil phase; b) a continuous aqueous phase comprising water; c) a thickening agent; d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; e) a pharmaceutically acceptable active agent; and f) optionally a dermatologically acceptable excipient. In one embodiment, the composition, in use, has a water vapor transmission rate of less than or about 75 g·m?2·hr?1 measured in vitro using the modWVTR test methodology.

Abstract: This invention refers to a pharmaceutical composition that comprises the synergic combination of a NSAID, such as the active ingredient: S-ketorolac of tromethamine and a GABA derivative agent, such as the active ingredient: gabapentin, which are formulated with pharmaceutically acceptable excipients in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of neuropathic and/or nociceptive pain caused by different etiologies.

Abstract: Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

Abstract: The present disclosure relates to a tongue spray containing gymnemic acid together with a form of exogenous ketones. The present disclosure also relates to methods of reducing or eliminating sugar consumption and reducing sugar withdrawal symptoms via administration of such composition to a subject.

Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.

Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.

Abstract: A method to increase the penetration of active agents through mucosal membranes, the method comprising the step of: a) administering to a subject in need a composition comprising: i) one or more hydrotropes in a total amount of less than 15% by weight of the composition; and ii) an active agent with a partition co-efficient (log P) or distribution coefficient (log D) of between 0 and 5.

Abstract: The present invention relates to an anti-aging composition. More specifically, the anti-aging composition according to the present invention is highly stable, harmless to the body, and effective in reducing wrinkles and improving elasticity of the skin due to the superb capability for stimulating collagen biosynthesis.

Abstract: Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

Abstract: The present invention is directed to a foaming composition comprising: from about 18% to about 36% of one or more anionic surfactants; from 0 0.1 to about 5% of one or more viscosity modifiers with a molecular weight of from about 38 to about 2800; from about 0.1 to about 10% of an anti-dandruff particulate; from about 1% to about 10% of a blowing agent, and wherein the foam density is from about 0.05 to about 0.25 g/ml.

Abstract: An object of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blister or erosion, etc. For example, the present invention can provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and an alcohol and/or a fatty acid having 12 or more carbon atoms.

Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.

Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.

Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.

Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Abstract: Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).